NCI advisors table proposed $186.5 million nanotechnology research program. NCI proposed to fund three to five “centers for cancer nanotechnology excellence,” a coordinating center, and training programs. Board members said they needed more time, information, to make decision. NCI director asked board to “think big” about nanotechnology. Deputy director called nanotechnology program “transformational.”
Also in this 8-page issue: John Montgomery, a founder of BioCryst Pharmaceuticals and a former member of the President’s Cancer Panel, dead.
DOD funds $4.2 million gynecologic oncology research program at four institutions.
June issue of Business & Regulatory Report included.
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Michael Caputo appointed to President’s Cancer Panel
The cancer survivor and political operative says his appointment signals Trump’s interest in cancer, survivorship - The Galleri MCD vote: What FDA asked its advisors to ignore
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish - FDA advisory committee votes in favor of Galleri approval, but calls for removal of “early” detection claims
Clinical benefit will not be considered for approval, FDA says
